- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 15.03. | Biogen's CMO Maha Radhakrishnan departs, leaving behind a legacy in Alzheimer's drug development | ||
| 15.03. | Hansoh, fresh from Big Pharma deal table, signs $690M ADC pact with Biotheus | ||
| 15.03. | Geron triumphs in FDA AdComm battle, securing 12-2 vote in favor of blood cancer drug imetelstat | ||
| 14.03. | Digital diabetes app maker Better Therapeutics shutters operations, lays off staff | ||
| 14.03. | Exact, Guardant tout successes of next-gen colorectal cancer screeners | ||
| 14.03. | Astellas puts the cork back in $350M Xork deal after Cartesian-Selecta merger | ||
| 14.03. | AstraZeneca inks $800M buyout of French biotech to snag phase 3 rare disease drug | ||
| 14.03. | Genmab grows up: Celebrating 25 years, CEO prepares to wield 'pretty good buying power' | ||
| 14.03. | Phase 2 fail sends OcuTerra's eye drop dreams down the drain | ||
| 14.03. | German biotech Tubulis rides wave of ADC interest to $138M financing round | ||
| 14.03. | Spruce's stock crashes as biotech lays off 5th of staff in wake of phase 2 hyperplasia fail | ||
| 13.03. | GE HealthCare launches philanthropic foundation aimed at maternal health | ||
| 13.03. | Medtronic, Edwards, Abbott tout TAVR data at CRT 2024 | ||
| 13.03. | J&J's John Reed takes home $20M-plus payday in his first year helming pharma R&D team | ||
| 13.03. | Almirall signs yes-nonsense skin disease deal with Eloxx for $3M upfront | ||
| 13.03. | Sanofi shutting down R&D site at UK biotech hub, displacing 90 workers | ||
| 13.03. | With first MASH drug due for FDA nod, Ionis says me too with phase 2 data | ||
| 13.03. | Novartis hits the cGAS, taking option to buy IFM unit for $90M upfront | ||
| 13.03. | As Crinetics nears FDA run for growth disease drug, a phase 2 test makes the case for carcinoid syndrome, too | ||
| 13.03. | Mallinckrodt, Silence collab to go quiet, but a phase 2 cardiovascular win speaks loudly for the biotech | ||
| 12.03. | Fortrea sells pair of businesses to private equity firm to become 'pure-play' CRO | ||
| 12.03. | In conversation with Medtronic's Frank Chan, head of its off-again, on-again acute care & monitoring division | ||
| 12.03. | Geron faces uphill battle at FDA meeting, as agency questions benefit-risk profile of imetelstat | ||
| 12.03. | Patient Square Capital aims to roll up NanoString assets with $220M bid | ||
| 12.03. | FDA hands Class I label to Abbott HeartMate LVAD software recall |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
